ArticleMolecular metabolism2025
Creatinine promotes adipose tissue wasting in chronic kidney disease via creatine and futile creatine cycle.
Article in Molecular metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveCachexia in chronic kidney disease (CKD) is a wasting syndrome. The futile creatine cycle (FCC) contributes to energy waste in adipocytes. Creatinine is metabolite of creatine. Whether creatinine involves in adipose wasting in CKD remains elusive.
methodsCachexia were assessed in unilateral ureteral obstruction induced CKD mice model. Cellular oxygen consumption and FCC-related genes expression were analyzed in adipocytes treated with creatinine in the presence of FCC inhibitor (SBI-425, inhibitor of TNAP) or creatine disruption (β-GPA, a creatine analogue that inhibits creatine transport into cells). The fate of labeled deuterated creatinine (D-3 creatinine) were traced by mass spectrometer. To determine creatinine drives adipose tissue wasting in vivo, two mice models of CKD were established by unilateral ureteral obstruction or renal ischemia and reperfusion injury. 206 patients diagnosed CKD were collected to analyze correlationship between creatinine in serum and adiposity.
resultsAdipose tissue wasting presented in CKD mice with serumal creatinine retention. In vitro, creatinine treatment at the concentration relevant of CKD elevated cellular oxygen consumption and FCC-related genes expression by converting into intracellular creatine. In the established CKD mice models, intraperitoneal injection of creatinine enhanced adipose tissue wasting, through increasing creatine accumulation. In contrast, disruption of creatine accumulation by β-GPA ameliorated tissue wasting. In patients with CKD, creatinine in serum negatively correlated with adiposity.
conclusionsOur results show that elevated serumal creatinine induces creatine accumulation, FCC activation and adipose tissue wasting in CKD, targeting creatinine-induced tissue wasting providing a promising therapeutic to ameliorate cachexia in CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.